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Heather S. L. Jim,1 Karen L. Syrjala,2 Doug Rizzo3Hematopoietic cell transplant survivors face a number of challenges including low energy and stamina,
“chemo-brain” and emotional distress, and late effects that can compromise functioning or lead to early mor-
tality. This session will review themost recent interventions and recommendations to avoid or mitigate these
complications.INTERVENTIONS TO IMPROVE ENERGYAND clear but is under investigation. Recent data have impli-
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Patients undergoing hematopoietic cell transplant
(HCT) experience significant fatigue and reduced
physical functioning before transplantation. Both allo-
geneic and autologous transplants are associated with
significant increases in fatigue in the acute posttrans-
plantation period. On average, fatigue and physical
functioning return to posttransplantation baseline in
the years following transplantation [1]. Nevertheless,
patients show significantly greater fatigue and reduced
physical functioning compared with individuals with-
out cancer [1]. Furthermore, fatigue and poor physical
functioning can be distressing because they can inter-
fere with return to work, school, and other daily activ-
ities [2]. As such, early identification and intervention
in patients at risk for fatigue and poor physical func-
tioning should be a high priority in supportive care.
Multiple mechanisms likely contribute to fatigue
and reduced physical functioning in cancer patients.
Data have implicated changes in energymetabolism, in-
flammation, and hypothalamic–pituitary–adrenal axis
activity in cancer patients, particularly those treated
with standard-dose chemotherapy.Depression andanx-
iety may also play a role in fatigue and reduced physical
functioning secondary to cancer. The extent to which
fatigue and reduced physical functioning result from
thesemechanisms in transplant patients is currently un-1Moffitt Cancer Center, Tampa, FL; 2Fred Hutchinson
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(eg, tumor necrosis factor, interleukin-1B, and
interleukin-6) as contributing to cancer-related fatigue
[3]. Research is currently under way to replicate these
findings in HCT patients.
A sizeable body of research suggests that behavioral
and pharmacologic interventions can prevent or reduce
physical deconditioning and improve quality of life in
HCT patients. Randomized clinical trials (RCTs) of
aerobic exercise and strength training have been con-
ducted in inpatient, outpatient rehabilitation, and
home-based settings. Supervised aerobic exercise in
these trials typically consists of use of a stationary
bicycle or treadmill 2 to 5 times per week, 20 to 30min-
utes per session, at a pace that elevates thepatient’s heart
rates. Strength training in these trials is typically con-
ducted using weights or stretch bands. Data suggest
that aerobic exercise and/or strength training can
prevent loss of physical performance during
hospitalization for transplantation, including loss of
physical endurance, muscle strength, and performance
status [4]. Aerobic exercise in the inpatient setting has
also been shown to reduce the negative effects of trans-
plantation on global quality of life and physical func-
tioning [4]. Effects of inpatient aerobic exercise and
strength trainingonother symptoms (eg, pain, diarrhea)
and immunologic parameters (eg, leukocytes, platelets,
time to engraftment) have been equivocal, however. Su-
pervised outpatient aerobic exercise and strength train-
ing in the posttransplantation period have been shown
to improve physical performance, including muscle
strength, walking speed, and walking distance [5].
Similar benefits have been observed in an RCT of
home-based aerobic exercise [6]. Additionally, non-
randomized studies suggest that aerobic exercise and
strength training may prevent or reduce fatigue and
increase vitality. Taken as a whole, existing literature
suggests that aerobic exercise and strength training
interventions are efficacious in improvingphysical func-
tioning in HCT patients. A large, multicenter RCT is
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home-based exercise in patients undergoing HCT.
Regarding pharmacologic interventions to reduce
cancer-related fatigue and increase energy, research
has been conducted on methylphenidate, dexmethyl-
phenidate, dexamphetamine, and modafinil. Of note,
no studies to date have yet examined these agents in
HCT patients. Nevertheless, a mix of prospective,
open-label studies and randomized, double-blind,
placebo-controlled studies in cancer patients suggest
that psychostimulants reduce fatigue. Some studies
also suggest that psychostimulants reduce depression
and pain [7,8], whereas effects on quality of life are
equivocal [8]. Only 2 studies have been published on
the effects of modafinil on cancer-related fatigue;
both were open-label studies and both reported signif-
icant reductions in fatigue [9,10]. Although some
studies have reported side effects of methylphenidate,
dexmethylphenidate, and dexamphetamine, including
insomnia, agitation, anorexia, nausea, vomiting, and
dry mouth [7], studies of modafinil have generally
reported that it was well tolerated. It should be noted,
however, that most studies of psychostimulants to
improve cancer-related fatigue have suffered from
methodologic limitations such as small sample sizes
and/or single-arm, open-label designs. As such, evi-
dence supporting the use of pharmacologic interven-
tions to reduce fatigue is preliminary but promising.
In summary, considerable progress has been made
in identifying fatigue and reduced physical functioning
as clinically relevant issues in HCT patients, under-
standing underlying mechanisms of cancer-related
fatigue, and developing behavioral and pharmacologic
interventions to increase energy and stamina. What is
now needed are large, multicenter RCTs demonstrat-
ing the effectiveness of behavioral and pharmacologic
interventions in the transplant setting. Additional
research is needed to identify patients at risk for signif-
icant fatigue and compromised physical functioning so
that they may benefit from early intervention.REFERENCES
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CHEMO-BRAIN AND EMOTIONAL DISTRESS
Karen L. Syrjala
Introduction
Accumulated evidence suggests 3 summary state-
ments about the cognitive and psychological health
of patients receivingHCT: (1) they are highly resilient,
and a majority will report competent cognitive
function and emotional stability; (2) during treatment,
a majority will manifest some decrements in both
emotional distress and cognitive function; (3) from
10% to 40% will report neurocognitive deficits or
psychologic needs that continue long term, depending
on what is measured and the subgroup evaluated.
Neurocognitive deficits
The term ‘‘chemo-brain’’ is a colloquial term for
a range of cognitive and psychomotor deficits that
include difficulties in 4 areas: memory, sustained atten-
tion and information processing speed, executive func-
tion or what is often called multitasking such as
shifting mental concepts, and hand–eye–brain coordi-
nation, also called psychomotor ability. Although
some debates have questioned whether chemo-brain
S14 Biol Blood Marrow Transplant 18:S12-S16, 2012H. S. L. Jim et al.syndromes exist after cancer treatment, this issue is
largely resolved with compelling longitudinal evidence
that cognitive function does decline after HCT and
recovers to some extent, but not entirely for all
survivors by 5 years [1].
Studies indicate that most survivors function
within the population-normative range after recovery
from HCT. Many enter transplantation with some
neurocognitive deficits particularly in memory, and
have generalized decrements in function immediately
following treatment. By 5 years, about 40% of HCT
survivors continue with deficits that are largely mild
[1]. Function recovers to within normal range in
most areas by 5 years after treatment. Psychomotor
function is particularly suppressed in about one-third
even 5 years after treatment, and does not fully recover
even after chronic graft-versus-host disease treatment
is discontinued [1,2]. Memory difficulties also con-
tinue long term; however, those at most risk seem to
have deficits that predate HCT [1,2]. Risk factors for
neurocognitive deficits include lower socioeconomic
status, total body irradiation, chronic graft-versus-
host disease and its treatment, and delirium during
acute treatment [1,3,4].
Studies testing cognitive rehabilitation interven-
tions post-HCT have not yet found improvements in
function. One barrier is that mechanisms for chemo-
brain are more speculative than definitive. Research
with non-HCT cancer survivors has demonstrated
variable efficacy in small studies to improve neurocog-
nitive function using medications such as methylphe-
nidate or modafinil. Studies that teach adults
compensatory mechanisms for managing cognitive
deficits have shown promise [5].
Emotional distress
Emotional distress is a broad term for a range of
psychosocial issues that transplant recipients experi-
ence, including anxiety and depression, panic, and
distress specific to their disease and transplant. Within
the context of treatment and cancer-related distress,
living with uncertainty and fear of recurrence domi-
nate. However, additional stress is attributed to
emotional issues such as posttraumatic stress, changes
in relationships, grief and loss, adaptation to new
limitations, demands such as work and financial limits,
medical demands, and changes in self-image. Increas-
ingly, researchers recognize that these negative
emotional outcomes are often balanced with positive
outcomes such as reappraisal of life priorities, benefit
finding, spiritual connection, and posttraumatic
growth.
Symptoms of emotional distress are most intense
before transplantation and gradually resolve over the
next 2 to 5 years [6]. Elevated levels of depression or
anxiety have been detected in over one-half of those as-
sessed pretransplantation and are associated with com-promised quality of life and increased rates ofmortality
[6-8]. In the posttransplantation period, depression,
anxiety, or posttraumatic stress have been identified
in over 40% of survivors [6,7]. Research clearly indi-
cates that spousal caregivers have even greater risk of
emotional turmoil than patients, with depression, anx-
iety, and marital dissatisfaction elevated beyond levels
seen in patients for the first 2 years after treatment.
Spouses report a higher rate of negative changes
(24%) than patients (15%), and patients report a higher
proportion of positive changes (85%) than spouses
(76%) [9]. Risk factors for psychological difficulties in-
clude more severe transplantation experience, less so-
cial constraint, greater spiritual well-being, and less
general anxiety [10]. This combination has predicted
56% of the variance in mental health in long-term sur-
vivors. Autologous HCT recipients have lower rates of
emotional distress only during the first 6 months after
treatment [6]. Age has not been found to be a risk fac-
tor for emotional distress. Although females are gener-
ally expected to report more emotional distress than
males, in transplantation this effect has not been con-
sistent. The strongest predictor of long-term emo-
tional health seems to be emotional health before
and immediately following transplantation. At the
most, one-half of HCT recipients with psychological
needs receive treatment.
Although clinical trials have demonstrated efficacy
in reducing distress in cancer patients, few of these
have yet been tested in HCT recipients. In addressing
emotional needs of HCT patients, 1 consideration is
that assessment is, in itself, a form of intervention
[7]. The distress thermometer, a tool first presented
through the National Comprehensive Cancer Net-
work guidelines, has demonstrated sensitivity and
specificity in screening for emotional distress in pa-
tients. Assessment provides an opportunity for the pa-
tient to begin talking about and labeling his or her
experiences and emotions. Indeed, this is the founda-
tion for most psychologic interventions. To better ad-
dress the emotional needs of HCT patients and
caregivers, the greatest research need is to develop
and test resource-conserving, sustainable interven-
tions targeted to those at greatest risk, which can be
provided through brief sessions, can be self-directed,
or that use technologies such as the phone or Internet
to reach long-term survivors.
Conclusions
Now that chemo-brain and emotional distress
complications have been well defined during and
followingHCT, further research needs tomore clearly
define risk factors and move toward understanding
the biologic and behavioral mechanisms, as well as
determining treatments for these complications that
have significant impact on long-term quality of
survival.
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PREVENTIVE PRACTICES FOR LONG-TERM
SURVIVORS OF HCT
Doug Rizzo
Approximately 50,000 patients undergo HCT
worldwide each year. Advances in transplantation
techniques and supportive care practices have led toprogressive improvements in survival for HCT
recipients in the last 2 decades. As patients survive
long term after transplantation, they are at risk for
developing late complications related to pre-, peri-,
and posttransplantation exposures. Recognizing the
need for systematic long-term follow-up of HCT sur-
vivors, the Center for International Blood andMarrow
Transplant Research, the European Group for Blood
and Marrow Transplantation, and the American
Society of Blood and Marrow Transplantation devel-
oped consensus recommendations for screening and
preventive practices for autologous and allogeneic
HCT survivors in 2006 [1,2]. The working group re-
convened in 2011 to update the guidelines, and invited
participants from other international HCT societies to
add a global perspective to the recommendations.
Updated recommendations will be presented.
The proposed guidelines focus on risks faced by
patients who have survived 6 months or more follow-
ing transplantation and address autologous and alloge-
neic, and pediatric and adult HCT recipients. Because
long-term HCT recipients may no longer be followed
by transplant centers and may have returned to the
care of community healthcare providers, the guide-
lines are geared toward providers who do not routinely
care for HCT recipients as well as those who do. To
improve accessibility of the guidelines for clinicians,
mobile applications are available for common cellular
phone platforms at (http://www.marrow.org/PHYSI
CIAN/Medical_Education/Clinical_Guidelines_App/
index.html). The National Marrow Donor Program
(NMDP) also publishes a patient-friendly version of
follow-up guidelines at (www.marrow.org).
Malignancy is the primary indication for HCT.
There has been increasing recognition of the role of
patients in their cancer survivorship experience. The
2006 Institute of Medicine Report ‘‘From Cancer
Patient to Cancer Survivor: Lost in Transition’’ high-
lights the importance of engaging cancer patients in
surveillance, recognition, and management of late
effects of treatment [3]. One of the primary recom-
mendations of this report is the provision of a compre-
hensive care summary and follow-up plan for every
patient. Further, it is recommended that the care plans
used by providers be based upon ‘‘systematically devel-
oped, evidence-based clinical practice guidelines,
assessment tools and screening instuments.’’ One of
the principal goals of the post-HCT recommendations
developed through this global collaboration is to
provide a template from which providers can engage
patients with treatment summaries and care plans.
We anticipate that patients may be able to use these
guidelines to establish a long-term follow-up care
plan in consultation with their healthcare providers
based on their individual exposures and risk factors.
Most of the recommendations were derived from
retrospective studies that have identified specific
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tors associated with them, although in some cases they
are based on evidence from non-HCT settings or
expert consensus. There remains a paucity of clinical
trials focused on screening and preventive practices
among HCT survivors, and the need for more re-
search in this area, including randomized or con-
trolled trials, is clear. The recommendations
represent sensible practices to optimize outcomes,
and although they are strongly encouraged for all re-
cipients, they should not be judged as mandatory. In
fact, it should be recognized that in some areas of
the world, resource constraints and access to medical
care after HCT may limit full implementation of the
recommendations.
A broad constellation of medical issues faced by
late survivors of transplantation are addressed. Aside
from health screening applicable to the general popu-
lation, recommendations are provided for complica-
tions involving the following systems: immunity and
infections, ocular, oral, respiratory, cardiovascular,
liver, genitourinary, muscle, and connective tissue,
skeletal, nervous system, endocrine, mucocutaneous,
psychosocial/sexual, and second malignancy screen-
ing. Althoughmost of the late complications addressed
pertain particularly to allogeneic recipients, autolo-
gous recipients are at risk for many of the late
complications and may experience unusual toxicity or
immune impairment following transplantation that
places them at risk similar to allogeneic recipients
(eg, exposure to prolonged steroids). Therefore,
although some of the recommendations do not
typically apply to autologous recipients, providers
should remain alert to these complications in all
patients.
The practice of HCT is continuously changing.
Some examples of such changes include emerging
indications of transplantation (eg, autoimmune
diseases, sickle cell disease), increased utilization of
newer donor sources (eg, umbilical cord blood and
haploidentical donors), decreased use of total body
irradiation for conditioning and evaluation of novel
therapies as part of HCT (eg, posttransplantation
maintenance therapy in myeloma). Nonmyeloablative
and reduced-intensity conditioning regimens offer the
ability to perform transplantation for a larger numberof older patients. The risks and constellation of late
complications may change as newer practices in trans-
plantation become more prevalent. Providers should
be cognizant of any unique exposures and risks
associated with these practices (eg, delayed immune
reconstitution in umbilical cord blood recipients)
when considering a long-term follow-up care plan
for their patients. These screening guidelines will
require additional revisions over time to accommodate
evolution in exposures associated with HCT.
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